Summary of Amgen's Conference Call Company Overview - **Company**: Amgen - **Industry**: Biotechnology and Pharmaceuticals - **Key Focus Areas**: Therapeutics for unmet medical needs, including cardiovascular diseases, osteoporosis, severe asthma, and rare diseases [2][3] Financial Performance - **2025 Revenue Growth**: 10% increase in revenues, driven by 14 blockbuster products [4] - **Earnings Growth**: 14% increase in earnings per share [4] - **Debt Reduction**: Over $6 billion in debt paid down in 2025 [6] Key Products and Growth Drivers - **Repatha**: - Annualized sales of approximately $3 billion, growing at 33% [7] - Demonstrated a 36% reduction in heart attack risk in primary prevention [5] - Significant market opportunity with over 100 million people at risk of heart attacks [9] - **Evenity**: - Sales growth of over 30%, targeting women at high risk of osteoporotic fractures [10] - Urgent need for treatment due to high mortality rates post-fracture [47] - **Tezspire**: - Innovative treatment for severe asthma and chronic rhinosinusitis with nasal polyps [10] - Strong clinical performance and potential for expansion into COPD and eosinophilic esophagitis [10] - **Biosimilars**: - 42% year-over-year sales growth, contributing $13 billion since entry into the market [15] - **Rare Disease Portfolio**: - Approached $5 billion in sales, with ongoing expansion into new indications [11] Pipeline and Future Prospects - **MariTide**: - Focused on obesity and type 2 diabetes, with six phase 3 studies initiated [19] - Potential for monthly or less frequent dosing, addressing treatment persistence issues [20][21] - **Olpazeran**: - Targets Lp(a) reduction, a significant risk factor for cardiovascular disease, with potential for 95%-100% reduction [38] - Expected to provide a long-acting treatment option for patients [39] - **Imdeltra**: - Bispecific T-cell engager for small cell lung cancer, showing promise in early lines of therapy [13] Market Dynamics and Strategic Focus - **Obesity Market**: - Anticipated growth due to increasing recognition of obesity as a chronic disease [29] - Amgen aims to position itself as a key player in this evolving landscape [30] - **Capital Allocation**: - Focus on investing in innovation and manufacturing capabilities to maintain competitive advantage [25] - **Technological Integration**: - Emphasis on incorporating technology and AI to enhance operational efficiency [24] Conclusion - Amgen is positioned for significant growth in 2026 and beyond, driven by a robust pipeline of innovative therapies and a strong financial foundation. The company is focused on addressing high unmet medical needs across various therapeutic areas, with a commitment to maintaining operational discipline and investing in future growth opportunities [27]

Core Insights - Amgen's experimental obesity drug MariTide has shown effectiveness in helping individuals maintain weight loss in an extension study [1] - A second mid-stage trial indicated that MariTide also reduced blood sugar levels in diabetes patients [1] Summary by Category Drug Efficacy - MariTide assists in weight maintenance post-weight loss, demonstrating its potential as a long-term treatment option for obesity [1] - The drug has shown promising results in lowering blood sugar levels among patients with diabetes, indicating its dual therapeutic potential [1]

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if the medication helps people maintain weight loss. ...

44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Provided January 12, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 2 We Have a Broad and Deep Portfolio Across Four Therapeutic Areas ROBERT A. BRADWAY, Chairman and Chief Executive Officer January 12, 2026 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs o ...

Group 1: Tariffs and Pharmaceutical Sector - President Trump has threatened pharmaceutical tariffs of up to 250% and 500% on India over Russian oil purchases, indicating a shift in the administration's approach to tariffs as a tool for industry reshaping rather than negotiation [2] - Johnson & Johnson (JNJ) has secured an exemption from certain tariffs by committing to lower drug prices, joining 14 other major pharmaceutical companies in the "TrumpRx" program, which aims to align US drug prices with European counterparts [3] - Moody's Analytics reported a "collapse in pharmaceutical imports" as companies stockpiled goods in anticipation of tariffs, demonstrating the market's tendency to react preemptively to presidential announcements [3] Group 2: Energy Sector and Venezuela - Following the capture of Venezuelan President Nicolás Maduro, President Trump declared a national emergency and announced new sanctions, leading to a surge in US energy stocks, with Chevron (CVX) rising 5% and Exxon Mobil (XOM) increasing by 2.2% [4] - However, by January 10, 2026, analysts expressed skepticism about the viability of Venezuelan oil investments, citing a lack of legal pathways and the need for significant infrastructure rebuilding [5] - Venezuelan government bonds saw a rally, with a bond maturing in 2027 increasing from 31.5p to over 40p on the dollar, indicating market interest despite the geopolitical instability [5] Group 3: Credit Card Industry - President Trump proposed a one-year, 10% cap on credit card interest rates, aiming to save Americans "tens of billions of dollars," which has raised concerns among banking executives [6][7] - The banking industry, including the Bank Policy Institute and the American Bankers Association, warned that such a cap could lead consumers to less regulated alternatives and reduce credit availability [8] - Major credit card companies like American Express (AXP) and JPMorgan Chase (JPM) experienced stock declines of -1.92% and -0.18% respectively, reflecting market apprehension about the proposed cap [8] Group 4: Defense Sector - President Trump's executive order threatening to restrict stock buybacks and dividends for defense contractors initially caused a drop in defense stocks, but a subsequent announcement of a $1.5 trillion defense budget for fiscal year 2027 led to a rally in the sector [9][10] - Northrop Grumman (NOC) saw a premarket increase of 6.8%, while Lockheed Martin (LMT) rose 6.7%, indicating strong market response to the budget announcement [10] - The iShares US Aerospace & Defense ETF gained approximately 55% over the past year, significantly outperforming the S&P 500's 17% increase, highlighting robust demand in the defense sector [10] Group 5: Market Reactions and Trends - The US stock market exhibited polarized performance on January 8, 2026, with the DOW gaining 60.94 points (+0.12%) while the S&P 500 and NASDAQ Composite fell [13] - By January 9, 2026, the indices largely recovered, with the S&P 500 climbing 0.6% and the DOW adding 0.5%, indicating a rotation out of high-growth technology into heavy industry [14] - Analysts forecast a 10% increase for the S&P 500 in the remainder of 2026, although they acknowledge that presidential tariffs pose a significant source of uncertainty for market performance [15]

Market Overview - The Dow Jones Industrial Average increased by 270.03 points (0.55%) to reach 49266.11, while Dow Futures rose by 144.00 points (0.29%) to 49637.00, indicating positive movement in the blue-chip index amidst a mixed broader market [1] - The S&P 500 remained essentially flat, and the Nasdaq Composite lagged due to declines in tech stocks [1] Economic Data Impact - The primary narrative driving the market was the release of US employment data, which showed fewer jobs added than expected but a lower unemployment rate [2] - Anticipation of a possible Supreme Court ruling on President Trump's tariffs contributed to market uncertainty [2] Sector Rotation - There was a notable rotation from high-flying tech stocks, particularly in the AI sector, into more defensive and value-oriented segments such as industrials and financials, driven by profit-taking and concerns over elevated valuations [2] Company Performance - Among the Dow's constituents, Home Depot (HD) led the gainers with a surge of 3.85%, followed by Nike (NKE) with a 3.02% increase, and Chevron (CVX) up 2.98% due to shifts in the oil market [3] - Other strong performers included Sherwin-Williams (SHW) (+2.90%) and Honeywell (HON) (+2.87%) [3] - Conversely, Amgen (AMGN) was the biggest decliner, falling by 3.26%, with Nvidia (NVDA) down 2.16% and Salesforce (CRM) down 2.06%, reflecting a broader pullback in technology and AI-related shares [3]

Key Points Building on a strong 2025, CVS Health's outlook for 2026 and beyond looks promising. Amgen is developing newer drug products that will address a recent patent cliff. Both stocks are strong options for dividend seekers to add to their portfolios. 10 stocks we like better than CVS Health › Last year was a rebound one for CVS Health (NYSE: CVS) and Amgen (NASDAQ: AMGN). After underperforming broader equities in 2024, both healthcare giants bounced back in 2025, outperforming the market ha ...

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow us on X (formerly kn ...

On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines.The acquisition values Dark Blue Therapeutics at up to $840 million, including upfront and future milestones.Why Is The Acquisition Important?Dark Blue’s lead candidate, DBT 3757, is currently in IND-enabling studies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).Leukemia is a cancer of the blood-forming tissues, like bone marrow, ...

Core Insights - Amgen has acquired Dark Blue Therapeutics for approximately $840 million, enhancing its oncology pipeline [1][8] - The acquisition adds a preclinical small-molecule degrader targeting MLLT1/3 proteins associated with specific types of acute myeloid leukemia (AML) [2][8] - Amgen currently does not market any therapies for AML but has Blincyto approved for acute lymphoblastic leukemia (ALL) and is developing bispecific T-cell engagers for AML [3][8] Amgen's Oncology Pipeline - Amgen has a diverse oncology portfolio, including drugs like Blincyto, Imdelltra, Lumakras, Vectibix, Kyprolis, Nplate, and Xgeva [6] - Key candidates in its late-stage oncology pipeline include bemarituzumab for gastric cancer and xaluritamig for metastatic castrate-resistant prostate cancer [6] - Ongoing phase III studies are evaluating Imdelltra in small cell lung cancer and biosimilars for Opdivo, Keytruda, and Ocrevus [6] Competitive Landscape - Major competitors in the oncology space include Pfizer, AstraZeneca, Merck, Johnson & Johnson, and Bristol-Myers [9] - Pfizer's oncology sales account for about 28% of total revenues, with a 7% increase in the first nine months of 2025 [10] - AstraZeneca's oncology segment comprises around 43% of total revenues, with a 16% increase in sales during the same period [11] - Merck's Keytruda, a key oncology drug, generated $23.3 billion in sales in the first nine months of 2025, up 8% year over year [12] - Bristol-Myers' Opdivo accounts for approximately 20% of its total revenues, with sales rising 8% to $7.54 billion [13] - Johnson & Johnson's oncology sales represent around 27% of total revenues, with a 20.6% operational increase in the first nine months of 2025 [14]